Theragenics® Acquires U.S. And Canadian Seed Business Of Eckert & Ziegler BEBIG, s.a.

BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation^®, a medical device company serving the cancer treatment and surgical product markets, announced it has acquired the U.S. and Canadian seed business of Eckert & Ziegler BEBIG, s.a. (“EZB”). This transaction, which was announced on November 30, 2015, closed on December 31, 2015. Financial terms were not disclosed.

“This transaction enhances our capabilities and expands our product portfolio for brachytherapy. Our legacy is improving lives and curing cancer. This transaction enhances our mission.”

Theragenics has acquired, among other things, the U.S. and Canadian customers of EZB, the U.S. and Canadian rights to the AnchorSeed^®, VariStrand™ and related seed products, and the rights to the SeedLock Needle™ product. These products will be added to Theragenics’ existing product portfolio. Theragenics will manufacture the products at its current facilities in Buford, Georgia.

“This transaction continues our long-standing commitment to prostate brachytherapy and the physicians and patients who depend on it,” stated Frank J. Tarallo, Chief Executive Officer of Theragenics Corporation. “As a leading manufacturer and supplier in this market, our focus has always been on quality and service. Theragenics has a long history of providing physicians with the tools necessary to achieve outstanding results for their patients. We welcome the EZB customers and look forward to working with their programs.”

Dr. Edgar Löffler, Managing Director of EZB, stated, “Theragenics has been recognized as a leader in prostate brachytherapy and has been a valued partner of EZB in the United States. I am confident that Theragenics will continue the outstanding quality and service to which the EZB customers and patients they serve have grown accustomed.”

Mr. Tarallo concluded, “This transaction enhances our capabilities and expands our product portfolio for brachytherapy. Our legacy is improving lives and curing cancer. This transaction enhances our mission.”

About Theragenics

Theragenics Corporation^® is a medical device company focusing on the cancer treatment and surgical products market. Theragenics’ brachytherapy business manufactures and sells products used primarily in the minimally invasive treatment of localized prostate cancer (www.theragenicsbrachy.com) and breast cancer. The surgical products business (www.cpmedical.com, www.galtneedletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. The surgical segment serves a number of markets including interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. For additional information, visit www.theragenics.com.